RPTX REPARE THERAPEUTICS INC revenue, earnings and financials
For the quarter ended September 30, 2025, REPARE THERAPEUTICS INC reported revenue of n/a, net income of $3.26M and diluted EPS of $0.08; for the fiscal year ended December 2024 revenue was n/a.
RPTX annual revenue and earnings
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$93.5M, net income −$84.7M (margin n/a), EPS −$2.00
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$116M, net income −$93.8M (margin n/a), EPS −$2.23
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$19.8M, net income −$29.0M (margin n/a), EPS −$0.69
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$109M, net income −$107M (margin n/a), EPS −$2.83
RPTX quarterly revenue and earnings
- Quarter ended Sep 30, 2025: revenue n/a, net income $3.26M, EPS $0.08
- Quarter ended Jun 30, 2025: revenue n/a, net income −$16.7M, EPS −$0.39
- Quarter ended Mar 31, 2025: revenue n/a, net income −$30.0M, EPS −$0.71
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$28.7M, EPS −$0.67
- Quarter ended Sep 30, 2024: revenue n/a, net income −$34.4M, EPS −$0.81
- Quarter ended Jun 30, 2024: revenue n/a, net income −$34.8M, EPS −$0.82
- Quarter ended Mar 31, 2024: revenue n/a, net income $13.2M, EPS $0.30
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$28.0M, EPS −$0.67
- Quarter ended Sep 30, 2023: revenue n/a, net income −$18.9M, EPS −$0.45
- Quarter ended Jun 30, 2023: revenue n/a, net income −$11.9M, EPS −$0.28
- Quarter ended Mar 31, 2023: revenue n/a, net income −$34.9M, EPS −$0.83
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$31.7M, EPS −$0.66
- Quarter ended Sep 30, 2022: revenue n/a, net income $75.5M, EPS $1.71
- Quarter ended Jun 30, 2022: revenue n/a, net income −$38.1M, EPS −$0.91
- Quarter ended Mar 31, 2022: revenue n/a, net income −$34.8M, EPS −$0.83
- Quarter ended Sep 30, 2021: revenue n/a, net income −$30.9M, EPS −$0.83
- Quarter ended Mar 31, 2021: revenue n/a, net income −$21.4M, EPS −$0.58
RPTX cash flow, buybacks and dividends
- Fiscal year ended Dec 2024: operating cash flow −$76.4M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$127M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow $322K, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$85.8M, share buybacks n/a
RPTX balance sheet
- Sep 30, 2025: cash $72.8M, total assets $127M, total liabilities $11.6M, shareholders' equity $115M
- Jun 30, 2025: cash $67.7M, total assets $130M, total liabilities $20.1M, shareholders' equity $110M
- Mar 31, 2025: cash $84.5M, total assets $144M, total liabilities $18.9M, shareholders' equity $125M
- Dec 31, 2024: cash $84.7M, total assets $177M, total liabilities $25.4M, shareholders' equity $151M
- Sep 30, 2024: cash $80.5M, total assets $206M, total liabilities $31.4M, shareholders' equity $175M
- Jun 30, 2024: cash $79.8M, total assets $235M, total liabilities $31.7M, shareholders' equity $204M
- Mar 31, 2024: cash $103M, total assets $263M, total liabilities $31.1M, shareholders' equity $232M
- Dec 31, 2023: cash $111M, total assets $254M, total liabilities $41.8M, shareholders' equity $212M
Is RPTX profitable?
No. REPARE THERAPEUTICS INC lost $72.2M over the last four quarters.
What is RPTX's EPS?
Diluted earnings per share over the last four quarters were −$1.69; $0.08 in the latest quarter.